Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in J Cancer Res Clin Oncol

Retrieve available abstracts of 130 articles:
HTML format



Single Articles


    January 2022
  1. NIEDER C, Aanes SG, Haukland E
    Primary systemic therapy for patients with brain metastases from lung cancer ineligible for targeted agents.
    J Cancer Res Clin Oncol. 2022 Jan 12. pii: 10.1007/s00432-022-03919.
    PubMed     Abstract available


  2. CHEN Y, Jin Y, Hu X, Chen M, et al
    Infiltrating T lymphocytes in the tumor microenvironment of small cell lung cancer: a state of knowledge review.
    J Cancer Res Clin Oncol. 2022 Jan 8. pii: 10.1007/s00432-021-03895.
    PubMed     Abstract available


  3. YU TT, Peng XC, Wang MF, Han N, et al
    Harnessing chlorin e6 loaded by functionalized iron oxide nanoparticles linked with glucose for target photodynamic therapy and improving of the immunogenicity of lung cancer.
    J Cancer Res Clin Oncol. 2022 Jan 8. pii: 10.1007/s00432-021-03879.
    PubMed     Abstract available


  4. XU Z, Hao X, Yang K, Wang Q, et al
    Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.
    J Cancer Res Clin Oncol. 2022 Jan 4. pii: 10.1007/s00432-021-03901.
    PubMed     Abstract available


  5. XU B, Cheng H, Li K, Lv Y, et al
    Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naive metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study.
    J Cancer Res Clin Oncol. 2022 Jan 1. pii: 10.1007/s00432-021-03873.
    PubMed     Abstract available


    December 2021
  6. WANG P, Yin T, Zhao K, Yu J, et al
    Correction to: Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Dec 8. pii: 10.1007/s00432-021-03877.
    PubMed    


  7. WEBER D, Decker M, Schuster M, Folz S, et al
    Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC.
    J Cancer Res Clin Oncol. 2021;147:3769-3771.
    PubMed     Abstract available


  8. WU H, Zhang Y, Hu H, Li Y, et al
    Ground glass opacity featured lung adenocarcinoma in teenagers.
    J Cancer Res Clin Oncol. 2021;147:3719-3724.
    PubMed     Abstract available


  9. NOMURA K, Aokage K, Nakai T, Sakashita S, et al
    Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2021;147:3699-3707.
    PubMed     Abstract available


  10. UEDA D, Ito M, Tsutani Y, Gimenez-Capitan A, et al
    Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung.
    J Cancer Res Clin Oncol. 2021;147:3709-3718.
    PubMed     Abstract available


    November 2021
  11. NEUMANN JM, Freitag H, Hartmann JS, Niehaus K, et al
    Subtyping non-small cell lung cancer by histology-guided spatial metabolomics.
    J Cancer Res Clin Oncol. 2021 Nov 28. pii: 10.1007/s00432-021-03834.
    PubMed     Abstract available


  12. NAKAMURA R, Yamada T, Morimoto K, Nakao A, et al
    Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2021 Nov 26. pii: 10.1007/s00432-021-03866.
    PubMed     Abstract available


  13. WANG P, Yin T, Zhao K, Yu J, et al
    Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Nov 23. pii: 10.1007/s00432-021-03849.
    PubMed     Abstract available


  14. CHEN Q, Li Y, Zhang W, Wang C, et al
    Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    J Cancer Res Clin Oncol. 2021 Nov 19. pii: 10.1007/s00432-021-03858.
    PubMed     Abstract available


  15. GAO X, Peng L, Zhang L, Huang K, et al
    Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Nov 8. pii: 10.1007/s00432-021-03848.
    PubMed     Abstract available


  16. FANG X, Wu G, Hua J, Zhao P, et al
    TCF-1(+) PD-1(+) CD8(+)T cells are associated with the response to PD-1 blockade in non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2021 Nov 2. pii: 10.1007/s00432-021-03845.
    PubMed     Abstract available


  17. UHLENBRUCH M, Kruger S
    Effect of antimicrobial therapy on progression-free survival of patients with non-small cell lung cancer receiving checkpoint inhibitor- and chemotherapy.
    J Cancer Res Clin Oncol. 2021 Nov 1. pii: 10.1007/s00432-021-03734.
    PubMed     Abstract available


    October 2021
  18. BAI R, Chen X, Song W, Tian H, et al
    Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns.
    J Cancer Res Clin Oncol. 2021 Oct 26. pii: 10.1007/s00432-021-03840.
    PubMed     Abstract available


  19. ZHOU L, Wang X, Lu J, Fu X, et al
    EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Oct 18. pii: 10.1007/s00432-021-03800.
    PubMed     Abstract available


  20. ZHAO Y, Wang H, He C
    Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    J Cancer Res Clin Oncol. 2021 Oct 18. pii: 10.1007/s00432-021-03828.
    PubMed     Abstract available


  21. ZENG J, Li X, Liang L, Duan H, et al
    Phosphorylation of CAP1 regulates lung cancer proliferation, migration, and invasion.
    J Cancer Res Clin Oncol. 2021 Oct 12. pii: 10.1007/s00432-021-03819.
    PubMed     Abstract available


    September 2021
  22. ROCHA ALG, da Conceicao MAM, da Cunha Sequeira Mano FXP, Martins HC, et al
    Metabolic active tumour volume quantified on [(18)F]FDG PET/CT further stratifies TNM stage IV non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2021 Sep 27. pii: 10.1007/s00432-021-03799.
    PubMed     Abstract available


  23. TANG X, Li Y, Qian WL, Yan WF, et al
    A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.
    J Cancer Res Clin Oncol. 2021 Sep 18. pii: 10.1007/s00432-021-03797.
    PubMed     Abstract available


  24. ZHONG Y, Wu Q, Wu S, Xie X, et al
    Comparing strategy of immune checkpoint inhibitors plus chemotherapy with chemotherapy alone for small cell lung cancer: a meta-analysis based on six RCTs incorporating 2800 participants.
    J Cancer Res Clin Oncol. 2021 Sep 17. pii: 10.1007/s00432-021-03798.
    PubMed     Abstract available


  25. OMORI S, Muramatsu K, Kawata T, Miyawaki E, et al
    Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.
    J Cancer Res Clin Oncol. 2021 Sep 17. pii: 10.1007/s00432-021-03784.
    PubMed     Abstract available


  26. POMPILI C, Dalmia S, McLennan Battleday F, Rogers Z, et al
    Factors influencing patient satisfaction after treatments for early-stage non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Sep 13. pii: 10.1007/s00432-021-03795.
    PubMed     Abstract available


  27. MORIMOTO K, Uchino J, Yokoi T, Kijima T, et al
    Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study.
    J Cancer Res Clin Oncol. 2021 Sep 12. pii: 10.1007/s00432-021-03782.
    PubMed     Abstract available


  28. KASHIWABARA K, Fujii S, Tsumura S, Sakamoto K, et al
    Efficacy and safety of transbronchial microwave ablation therapy under moderate sedation in malignant central airway obstruction patients with respiratory failure: a single-institution retrospective study.
    J Cancer Res Clin Oncol. 2021;147:2751-2757.
    PubMed     Abstract available


  29. GROGG JB, Fronzaroli JN, Oliveira P, Bode PK, et al
    Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data.
    J Cancer Res Clin Oncol. 2021;147:2671-2679.
    PubMed     Abstract available


    August 2021
  30. WANG F, Jin F, Cheng B, Zhang Y, et al
    The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Aug 6. pii: 10.1007/s00432-021-03752.
    PubMed     Abstract available


  31. IANZA A, Di Chicco A, Biagi C, Giudici F, et al
    EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.
    J Cancer Res Clin Oncol. 2021;147:2301-2307.
    PubMed     Abstract available


  32. LI P, Hou F, Wang S, Luo N, et al
    A novel NECTIN4-NTRK1 fusion identified in a lung squamous cell carcinoma patient with MSI-H.
    J Cancer Res Clin Oncol. 2021;147:2483-2486.
    PubMed    


    July 2021
  33. HIZAL M, Bilgin B, Paksoy N, Acikgoz O, et al
    The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.
    J Cancer Res Clin Oncol. 2021 Jul 31. pii: 10.1007/s00432-021-03748.
    PubMed     Abstract available


  34. YANG Z, Yu R, Deng W, Wang W, et al
    Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer.
    J Cancer Res Clin Oncol. 2021 Jul 29. pii: 10.1007/s00432-021-03740.
    PubMed     Abstract available


  35. SU Z, Jiang Y, Li C, Zhong R, et al
    Relationship between lung function and lung cancer risk: a pooled analysis of cohorts plus Mendelian randomization study.
    J Cancer Res Clin Oncol. 2021 Jul 27. pii: 10.1007/s00432-021-03619.
    PubMed     Abstract available


  36. OTA T, Kirita K, Matsuzawa R, Udagawa H, et al
    Correction to: Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified.
    J Cancer Res Clin Oncol. 2021 Jul 23. pii: 10.1007/s00432-021-03737.
    PubMed    


  37. SUN J, Zhang J, Hu H, Qin H, et al
    Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer.
    J Cancer Res Clin Oncol. 2021 Jul 21. pii: 10.1007/s00432-021-03735.
    PubMed     Abstract available


  38. BRANCHER S, Ribeiro AE, Toporcov TN, Weiderpass E, et al
    The role of metformin on lung cancer survival: the first systematic review and meta-analysis of observational studies and randomized clinical trials.
    J Cancer Res Clin Oncol. 2021 Jul 15. pii: 10.1007/s00432-021-03728.
    PubMed     Abstract available


  39. GUO R, Zhang Y, Ma Z, Deng C, et al
    Overuse of follow-up chest computed tomography in patients with incidentally identified nodules suspicious for lung cancer.
    J Cancer Res Clin Oncol. 2021 Jul 8. pii: 10.1007/s00432-021-03692.
    PubMed     Abstract available


  40. HE X, Ma X, Wang C, Luan M, et al
    The peptide mimicking small extracellular ring domain of CD82 inhibits tumor cell migration in vitro and metastasis in vivo.
    J Cancer Res Clin Oncol. 2021;147:1927-1934.
    PubMed     Abstract available


  41. LIU J, Hao J, Niu Y, Wu X, et al
    Network pharmacology-based and clinically relevant prediction of active ingredients and potential targets of Chinese herbs on stage IV lung adenocarcinoma patients.
    J Cancer Res Clin Oncol. 2021;147:2079-2092.
    PubMed     Abstract available


    June 2021
  42. DOU Y, Duan Q, Qi C, Hou L, et al
    An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2021;147:1865-1867.
    PubMed     Abstract available


    May 2021
  43. SHEN Z, Chen C, Sun J, Huang J, et al
    The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer.
    J Cancer Res Clin Oncol. 2021 May 26. pii: 10.1007/s00432-021-03640.
    PubMed     Abstract available


  44. ZHANG Y, Zhang Z, Ding Y, Fang Y, et al
    Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2021 May 25. pii: 10.1007/s00432-021-03613.
    PubMed     Abstract available


  45. ZHAO Y, Liu Y, Li S, Peng Z, et al
    Role of lung and gut microbiota on lung cancer pathogenesis.
    J Cancer Res Clin Oncol. 2021 May 20. pii: 10.1007/s00432-021-03644.
    PubMed     Abstract available


  46. DAI Y, Zhong F, Liu W, Song Q, et al
    Mycoplasma hyorhinis infection promotes tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients.
    J Cancer Res Clin Oncol. 2021;147:1379-1388.
    PubMed     Abstract available


  47. FRANZESE C, Badalamenti M, Teriaca A, De Virgilio A, et al
    Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
    J Cancer Res Clin Oncol. 2021;147:1307-1313.
    PubMed     Abstract available


    April 2021
  48. LEONETTI A, Carbone D, Gregori A, Tiseo M, et al
    A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?
    J Cancer Res Clin Oncol. 2021 Apr 26. pii: 10.1007/s00432-021-03647.
    PubMed    


  49. QIU X, Zhang H, Zhao Y, Zhao J, et al
    Application of circulating genetically abnormal cells in the diagnosis of early-stage lung cancer.
    J Cancer Res Clin Oncol. 2021 Apr 24. pii: 10.1007/s00432-021-03648.
    PubMed     Abstract available


  50. NOUNU A, Walker V, Richmond RC
    Correction to: Letter regarding, "Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses".
    J Cancer Res Clin Oncol. 2021 Apr 11. pii: 10.1007/s00432-021-03636.
    PubMed    


  51. WEI T, Song J, Liang K, Li L, et al
    Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.
    J Cancer Res Clin Oncol. 2021;147:1049-1064.
    PubMed     Abstract available


  52. ZHANG G, Cao Y, Zhang J, Zhao Z, et al
    Epidermal growth factor receptor mutations in lung adenocarcinoma: associations between dual-energy spectral CT measurements and histologic results.
    J Cancer Res Clin Oncol. 2021;147:1169-1178.
    PubMed     Abstract available


    March 2021
  53. HARA N, Ichihara E, Harada D, Inoue K, et al
    Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    J Cancer Res Clin Oncol. 2021 Mar 29. pii: 10.1007/s00432-021-03615.
    PubMed     Abstract available


  54. PATEL MA, Fazli Y, Sivakumar S, Dennis C, et al
    Brachytherapy vs external beam therapy among NSCLC patients undergoing limited surgical resection.
    J Cancer Res Clin Oncol. 2021;147:853-861.
    PubMed     Abstract available


  55. HUANG D, Cui P, Huang Z, Wu Z, et al
    Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2021;147:881-891.
    PubMed     Abstract available


  56. LIN M, Qu M, Huang W, Liu T, et al
    Clinical effectiveness of percutaneous vertebroplasty in conjunction with postoperative radiotherapy in the treatment of spinal metastases.
    J Cancer Res Clin Oncol. 2021;147:835-844.
    PubMed     Abstract available


    February 2021
  57. FENG M, Ye X, Chen B, Zhang J, et al
    Detection of circulating genetically abnormal cells using 4-color fluorescence in situ hybridization for the early detection of lung cancer.
    J Cancer Res Clin Oncol. 2021 Feb 6. pii: 10.1007/s00432-021-03517.
    PubMed     Abstract available


  58. BILGIN B, Sendur MAN, Yucel S, Hizal M, et al
    The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement.
    J Cancer Res Clin Oncol. 2021 Feb 2. pii: 10.1007/s00432-021-03546.
    PubMed     Abstract available


  59. PARK JH, You GL, Ahn MJ, Kim SW, et al
    Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
    J Cancer Res Clin Oncol. 2021 Feb 1. pii: 10.1007/s00432-021-03527.
    PubMed     Abstract available


  60. BI Y, Jiang Y, Li X, Hou G, et al
    Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/beta-catenin signaling and autophagy.
    J Cancer Res Clin Oncol. 2021;147:499-505.
    PubMed     Abstract available


  61. CHANG Y, Zhao C, Ding H, Wang T, et al
    Serum factor(s) from lung adenocarcinoma patients regulates the molecular clock expression.
    J Cancer Res Clin Oncol. 2021;147:493-498.
    PubMed     Abstract available


  62. CAROSIO R, Fontana V, Mastracci L, Ferro P, et al
    Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
    J Cancer Res Clin Oncol. 2021;147:459-468.
    PubMed     Abstract available


    January 2021
  63. LI X, Liu L, Song X, Wang K, et al
    TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12 as novel biomarkers for lung cancer diagnosis and progression prediction.
    J Cancer Res Clin Oncol. 2021 Jan 29. pii: 10.1007/s00432-020-03502.
    PubMed     Abstract available


  64. YANG M, Li Z, Tao J, Hu H, et al
    Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells.
    J Cancer Res Clin Oncol. 2021 Jan 20. pii: 10.1007/s00432-021-03510.
    PubMed     Abstract available


  65. NOUNU A, Walker V, Richmond RC
    Letter regarding, "Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses".
    J Cancer Res Clin Oncol. 2021 Jan 12. pii: 10.1007/s00432-020-03508.
    PubMed    


  66. BILGIN B, Sendur MAN, Yucel S, Celik E, et al
    Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
    J Cancer Res Clin Oncol. 2021 Jan 12. pii: 10.1007/s00432-020-03501.
    PubMed     Abstract available


  67. FU F, Zhang Y, Gao Z, Zhao Y, et al
    Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Jan 4. pii: 10.1007/s00432-020-03477.
    PubMed     Abstract available


  68. XIN S, Fang W, Li J, Li D, et al
    Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2021 Jan 2. pii: 10.1007/s00432-020-03476.
    PubMed     Abstract available


  69. MATSUBARA T, Yamaguchi M, Jinnouchi M, Takamori S, et al
    Clinical course and prognosis of patients with lung cancer who develop anticancer therapy-related pneumonitis.
    J Cancer Res Clin Oncol. 2021 Jan 2. pii: 10.1007/s00432-020-03478.
    PubMed     Abstract available


  70. WU Z, Huang T, Zhang S, Cheng D, et al
    A prediction model to evaluate the pretest risk of malignancy in solitary pulmonary nodules: evidence from a large Chinese southwestern population.
    J Cancer Res Clin Oncol. 2021;147:275-285.
    PubMed     Abstract available


  71. MASUDA K, Horinouchi H, Tanaka M, Higashiyama R, et al
    Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    J Cancer Res Clin Oncol. 2021;147:245-251.
    PubMed     Abstract available


    December 2020
  72. NADLER E, Arondekar B, Aguilar KM, Zhou J, et al
    Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
    J Cancer Res Clin Oncol. 2020 Dec 2. pii: 10.1007/s00432-020-03414.
    PubMed     Abstract available


    November 2020
  73. RACHOW T, Schiffl H, Lang SM
    Risk of lung cancer and renin-angiotensin blockade: a concise review.
    J Cancer Res Clin Oncol. 2020 Nov 24. pii: 10.1007/s00432-020-03445.
    PubMed     Abstract available


  74. SHU Z, Dong B, Shi L, Shen W, et al
    Correction to: Stereotactic body radiotherapy for elderly patients (>/= 75 years) with earlystage nonsmall cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Nov 23. pii: 10.1007/s00432-020-03469.
    PubMed     Abstract available


  75. HAO S, Liu J, Ma J
    Further discussion on the association between desmoglein 2 and tumor size of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Nov 22. pii: 10.1007/s00432-020-03465.
    PubMed     Abstract available


  76. ZHENG Q, Huang Y, Zeng X, Chen X, et al
    Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
    J Cancer Res Clin Oncol. 2020 Nov 16. pii: 10.1007/s00432-020-03444.
    PubMed     Abstract available


  77. ARAGAKI M, Hida Y, Kato T, Fujiwara-Kuroda A, et al
    Feasibility of limited resection for peripheral small-sized non-small cell lung cancer: a retrospective single-center-based study.
    J Cancer Res Clin Oncol. 2020 Nov 5. pii: 10.1007/s00432-020-03441.
    PubMed     Abstract available


  78. CHEN S, Bao Y, Xu J, Zhang X, et al
    Efficacy and safety of TCM combined with chemotherapy for SCLC: a systematic review and meta-analysis.
    J Cancer Res Clin Oncol. 2020;146:2913-2935.
    PubMed     Abstract available


  79. WANG F, Zhao N, Gao G, Deng HB, et al
    Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2020;146:2851-2859.
    PubMed     Abstract available


  80. YANG J, Wu Z, Chen Y, Hu C, et al
    Pre-treatment with Bifidobacterium infantis and its specific antibodies enhance targeted radiosensitization in a murine model for lung cancer.
    J Cancer Res Clin Oncol. 2020 Nov 1. pii: 10.1007/s00432-020-03434.
    PubMed     Abstract available


    October 2020
  81. LI L, Pan Y, Mo X, Wei T, et al
    A novel metastatic promoter CEMIP and its downstream molecular targets and signaling pathway of cellular migration and invasion in SCLC cells based on proteome analysis.
    J Cancer Res Clin Oncol. 2020;146:2519-2534.
    PubMed     Abstract available


  82. TAKADA K, Toyokawa G, Kinoshita F, Jogo T, et al
    Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
    J Cancer Res Clin Oncol. 2020;146:2639-2650.
    PubMed     Abstract available


    September 2020
  83. SAKAI T, Udagawa H, Matsumoto S, Yoh K, et al
    Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Sep 30. pii: 10.1007/s00432-020-03413.
    PubMed     Abstract available


  84. XIAN W, Shen J, Zhou H, Liu J, et al
    Mendelian randomization study indicates lack of causal relationship between physical activity and lung cancer.
    J Cancer Res Clin Oncol. 2020 Sep 28. pii: 10.1007/s00432-020-03409.
    PubMed     Abstract available


  85. JIANG Y, Su Z, Li C, Wang R, et al
    Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses.
    J Cancer Res Clin Oncol. 2020 Sep 23. pii: 10.1007/s00432-020-03394.
    PubMed     Abstract available


  86. LI Q, Zhu X, Song W, Peng X, et al
    The P2X7 purinergic receptor: a potential therapeutic target for lung cancer.
    J Cancer Res Clin Oncol. 2020 Sep 5. pii: 10.1007/s00432-020-03379.
    PubMed     Abstract available


  87. ZHOU X, Xu X, Tian Z, Xu WY, et al
    Mutational profiling of lung adenocarcinoma in China detected by next-generation sequencing.
    J Cancer Res Clin Oncol. 2020;146:2277-2287.
    PubMed     Abstract available


  88. LIU J, Yang X, Zhang L, Yang B, et al
    Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2020;146:2299-2310.
    PubMed     Abstract available


  89. FRANZESE C, Bonu ML, Comito T, Clerici E, et al
    Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    J Cancer Res Clin Oncol. 2020;146:2289-2297.
    PubMed     Abstract available


  90. KIM SA, Kim JW, Suh KJ, Chang W, et al
    Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
    J Cancer Res Clin Oncol. 2020;146:2399-2410.
    PubMed     Abstract available


  91. ZHANG Y, Deng C, Ma X, Gao Z, et al
    Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy.
    J Cancer Res Clin Oncol. 2020;146:2411-2417.
    PubMed     Abstract available


    August 2020
  92. ZHOU L, Zhang M, Li R, Xue J, et al
    Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.
    J Cancer Res Clin Oncol. 2020 Aug 28. pii: 10.1007/s00432-020-03360.
    PubMed     Abstract available


  93. MA X, Wang S, Zhang Y, Wei H, et al
    Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC).
    J Cancer Res Clin Oncol. 2020 Aug 27. pii: 10.1007/s00432-020-03362.
    PubMed     Abstract available


  94. DU TQ, Li X, Zhong WS, Tian JD, et al
    Brain metastases of lung cancer: comparison of survival outcomes among whole brain radiotherapy, whole brain radiotherapy with consecutive boost, and simultaneous integrated boost.
    J Cancer Res Clin Oncol. 2020 Aug 26. pii: 10.1007/s00432-020-03359.
    PubMed     Abstract available


  95. KASHIWABARA K, Fujii S, Tsumura S, Sakamoto K, et al
    Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.
    J Cancer Res Clin Oncol. 2020 Aug 6. pii: 10.1007/s00432-020-03344.
    PubMed     Abstract available


    July 2020
  96. CHEN SS, Li K, Wu J, Peng ZY, et al
    Stem signatures associated antibodies yield early diagnosis and precise prognosis predication of patients with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Jul 20. pii: 10.1007/s00432-020-03325.
    PubMed     Abstract available


  97. LATHWAL A, Kumar R, Arora C, Raghava GPS, et al
    Identification of prognostic biomarkers for major subtypes of non-small-cell lung cancer using genomic and clinical data.
    J Cancer Res Clin Oncol. 2020 Jul 14. pii: 10.1007/s00432-020-03318.
    PubMed     Abstract available


  98. BIAN J, Yan K, Liu N, Xu X, et al
    Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Jul 13. pii: 10.1007/s00432-020-03244.
    PubMed     Abstract available


  99. HUO Y, Guo Z, Gao X, Liu Z, et al
    Case study of an autoantibody panel for early detection of lung cancer and ground-glass nodules.
    J Cancer Res Clin Oncol. 2020 Jul 9. pii: 10.1007/s00432-020-03309.
    PubMed     Abstract available


  100. LANDRE T, Des Guetz G, Chouahnia K, Duchemann B, et al
    First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.
    J Cancer Res Clin Oncol. 2020 Jul 7. pii: 10.1007/s00432-020-03311.
    PubMed     Abstract available


  101. KO KH, Huang HK, Chen YI, Chang H, et al
    Surgical outcomes of second primary lung cancer after the extrapulmonary malignancy.
    J Cancer Res Clin Oncol. 2020 Jul 6. pii: 10.1007/s00432-020-03310.
    PubMed     Abstract available


  102. ZENG Y, Li N, Liu W, Zeng M, et al
    Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Jul 5. pii: 10.1007/s00432-020-03288.
    PubMed     Abstract available


  103. ZHAO Y, Pan Y, Cheng C, Zheng D, et al
    EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.
    J Cancer Res Clin Oncol. 2020;146:1781-1789.
    PubMed     Abstract available


  104. JU Q, Zhao YJ, Ma S, Li XM, et al
    Genome-wide analysis of prognostic-related lncRNAs, miRNAs and mRNAs forming a competing endogenous RNA network in lung squamous cell carcinoma.
    J Cancer Res Clin Oncol. 2020;146:1711-1723.
    PubMed     Abstract available


    June 2020
  105. LI WQ, Cui JW
    Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments.
    J Cancer Res Clin Oncol. 2020 Jun 28. pii: 10.1007/s00432-020-03296.
    PubMed     Abstract available


  106. KIM SH, Choi CM, Lee DH, Kim SW, et al
    Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
    J Cancer Res Clin Oncol. 2020 Jun 24. pii: 10.1007/s00432-020-03293.
    PubMed     Abstract available


  107. XIE J, Zhang X, Hu S, Peng WD, et al
    Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion.
    J Cancer Res Clin Oncol. 2020 Jun 12. pii: 10.1007/s00432-020-03276.
    PubMed     Abstract available


  108. ZHOU H, Sun Y, Xiu W, Han J, et al
    Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer.
    J Cancer Res Clin Oncol. 2020 Jun 9. pii: 10.1007/s00432-020-03282.
    PubMed     Abstract available


  109. HUI Z, Wei F, Ren H, Xu W, et al
    Primary tumor standardized uptake value (SUVmax) measured on (18)F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Jun 3. pii: 10.1007/s00432-020-03240.
    PubMed     Abstract available


  110. LUO G, Tang M, Zhao Q, Lu L, et al
    Bone marrow adipocytes enhance osteolytic bone destruction by activating 1q21.3(S100A7/8/9-IL6R)-TLR4 pathway in lung cancer.
    J Cancer Res Clin Oncol. 2020 Jun 3. pii: 10.1007/s00432-020-03277.
    PubMed     Abstract available


  111. ZHAO M, Chen Z, Zheng Y, Liang J, et al
    Identification of cancer stem cell-related biomarkers in lung adenocarcinoma by stemness index and weighted correlation network analysis.
    J Cancer Res Clin Oncol. 2020;146:1463-1472.
    PubMed     Abstract available


  112. WEN Z, Zhao Y, Fu F, Hu H, et al
    Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2 cm or less in diameter.
    J Cancer Res Clin Oncol. 2020;146:1603-1613.
    PubMed     Abstract available


    May 2020
  113. AARNINK A, Fumet JD, Favier L, Truntzer C, et al
    Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
    J Cancer Res Clin Oncol. 2020 May 30. pii: 10.1007/s00432-020-03262.
    PubMed     Abstract available


  114. HAKOZAKI T, Hosomi Y, Shimizu A, Kitadai R, et al
    Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
    J Cancer Res Clin Oncol. 2020 May 27. pii: 10.1007/s00432-020-03252.
    PubMed     Abstract available


  115. HAKOZAKI T, Hosomi Y, Kitadai R, Kitagawa S, et al
    Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer.
    J Cancer Res Clin Oncol. 2020 May 27. pii: 10.1007/s00432-020-03271.
    PubMed     Abstract available


  116. ESAGIAN SM, Grigoriadou GIota, Nikas IP, Boikou V, et al
    Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review.
    J Cancer Res Clin Oncol. 2020 May 27. pii: 10.1007/s00432-020-03267.
    PubMed     Abstract available


  117. ZHU HZ, Fang CJ, Guo Y, Zhang Q, et al
    Detection of miR-155-5p and imaging lung cancer for early diagnosis: in vitro and in vivo study.
    J Cancer Res Clin Oncol. 2020 May 23. pii: 10.1007/s00432-020-03246.
    PubMed     Abstract available


  118. MU Y, Hao X, Xing P, Hu X, et al
    Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    J Cancer Res Clin Oncol. 2020 May 8. pii: 10.1007/s00432-020-03239.
    PubMed     Abstract available


  119. RANA RH, Alam F, Alam K, Gow J, et al
    Gender-specific differences in care-seeking behaviour among lung cancer patients: a systematic review.
    J Cancer Res Clin Oncol. 2020;146:1169-1196.
    PubMed     Abstract available


  120. CHEN YY, Huang YJ, Huang HK, Chang H, et al
    The prognostic factors of recurrence and survival in female patients with lung adenocarcinoma and breast cancer.
    J Cancer Res Clin Oncol. 2020;146:1299-1306.
    PubMed     Abstract available


  121. OKI T, Aokage K, Nomura S, Tane K, et al
    Optimal method for measuring invasive size that predicts survival in invasive mucinous adenocarcinoma of the lung.
    J Cancer Res Clin Oncol. 2020;146:1291-1298.
    PubMed     Abstract available


  122. ZHOU C, Li W, Shao J, Zhao J, et al
    Thoracic solitary fibrous tumors: an analysis of 70 patients who underwent surgical resection in a single institution.
    J Cancer Res Clin Oncol. 2020;146:1245-1252.
    PubMed     Abstract available


  123. FRANZESE C, Comito T, Franceschini D, Loi M, et al
    Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy.
    J Cancer Res Clin Oncol. 2020;146:1227-1234.
    PubMed     Abstract available


    April 2020
  124. LI A, Cao W, Liu X, Zhang Y, et al
    Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    J Cancer Res Clin Oncol. 2020 Apr 27. pii: 10.1007/s00432-020-03228.
    PubMed     Abstract available


  125. LIU J, Mao G, Li Y, Tao L, et al
    Targeted deep sequencing helps distinguish independent primary tumors from intrapulmonary metastasis for lung cancer diagnosis.
    J Cancer Res Clin Oncol. 2020 Apr 24. pii: 10.1007/s00432-020-03227.
    PubMed     Abstract available


  126. LI N, Zeng Y, Huang J
    Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer.
    J Cancer Res Clin Oncol. 2020 Apr 7. pii: 10.1007/s00432-020-03188.
    PubMed     Abstract available


  127. YOU H, Zhang YZ, Lai HL, Li D, et al
    Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Apr 4. pii: 10.1007/s00432-020-03189.
    PubMed     Abstract available


  128. GUO W, Sun S, Guo L, Song P, et al
    Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics.
    J Cancer Res Clin Oncol. 2020;146:821-841.
    PubMed     Abstract available


  129. MORMILE R
    Hyperthermia, positive feedback loop with IL-6 and risk of NSCLC progression: a tangle to unravel?
    J Cancer Res Clin Oncol. 2020;146:1101-1102.
    PubMed     Abstract available


    March 2020
  130. CHEN H, Wang A, Wang J, He Z, et al
    Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.
    J Cancer Res Clin Oncol. 2020 Mar 27. pii: 10.1007/s00432-020-03192.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: